SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

Search

BioMerieux

Fechado

SetorSaúde

115.5 1.49

Visão Geral

Variação de preço das ações

24h

Atual

Mín

113.8

Máximo

115.8

Indicadores-chave

By Trading Economics

Rendimento

215M

Vendas

785M

P/E

Médio do Setor

31.236

57.333

Rendimento de Dividendos

0.79

Margem de lucro

11.32

Funcionários

14,147

EBITDA

161M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+16.61% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.79%

2.63%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-117M

13B

Abertura anterior

114.01

Fecho anterior

115.5

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

BioMerieux Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de abr. de 2025, 08:49 UTC

Grandes Movimentos do Mercado

BioMerieux Shares Fall After Warning on Currency-Exchange Hit

Comparação entre Pares

Variação de preço

BioMerieux Previsão

Preço-alvo

By TipRanks

16.61% parte superior

Previsão para 12 meses

Média 133.17 EUR  16.61%

Máximo 140 EUR

Mínimo 127 EUR

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para BioMerieux - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

113.8 / 118.9Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.